Title |
Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials
|
---|---|
Published in |
Trials, December 2014
|
DOI | 10.1186/1745-6215-15-486 |
Pubmed ID | |
Authors |
Beena G Sood, Martin Keszler, Meena Garg, Jonathan M Klein, Robin Ohls, Namasivayam Ambalavanan, C Michael Cotten, Monica Malian, Pablo J Sanchez, Satyan Lakshminrusimha, Leif D Nelin, Krisa P Van Meurs, Rebecca Bara, Shampa Saha, Abhik Das, Dennis Wallace, Rosemary D Higgins, Seetha Shankaran, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network |
Abstract |
Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of infants. Aerosolized prostaglandins I2 (PGI2) and E1 (PGE1) have been reported to be effective selective pulmonary vasodilators. The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of inhaled PGE1 (IPGE1) in NHRF. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 67 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 15% |
Student > Master | 8 | 12% |
Student > Bachelor | 8 | 12% |
Student > Ph. D. Student | 6 | 9% |
Student > Postgraduate | 6 | 9% |
Other | 11 | 16% |
Unknown | 18 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 28 | 42% |
Nursing and Health Professions | 5 | 7% |
Biochemistry, Genetics and Molecular Biology | 3 | 4% |
Agricultural and Biological Sciences | 2 | 3% |
Computer Science | 2 | 3% |
Other | 9 | 13% |
Unknown | 18 | 27% |